Propylnorapomorphine
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| Density | 1.2 g/cm3 |
| Boiling point | 446 to 536 °C (835 to 997 °F) [1] |
| |
N-n-Propylnorapomorphine (NPA) is an
the latter of which overcomes the former to increase postsynaptic dopaminergic signaling only with high doses.